PDE10A and dementia: The pharmacokinetic and biochemical results obtained support the notion that these novel prototype dual-acting compounds combining the pharmacophores relevant for PDE10A and 5-HT1AR/5-HT7R activity might offer a promising therapeutic tool in CNS-connected disorders, especially for NPS in dementia patients.